Background
==========

Alzheimer\'s disease (AD) is the most common cause of dementia and the most prevalent neurodegenerative disorder. An estimated 10 percent of Americans over the age of 65 and half of those over age 85 have AD. More than 4.5 million Americans currently suffer from the disease. In autosomal dominant early-onset Alzheimer\'s disease (EOAD, age of onset \< 60 years), three susceptible genes (*APP*, *PSEN1*, and *PSEN2*) have been identified \[[@B1],[@B2]\]. Late-onset AD (LOAD) has \~80% heritability, and is strongly associated with apolipoprotein E (*APOE*) \[[@B3]\]. APOE has three major alleles (ε2/ε3/ε4) that have different effects on the risk of LOAD, with ε4 having between 10 and 30 times of risk of developing AD by 75 years of age \[[@B4]\].

In addition, several genetic studies have identified putative susceptible loci and genetic variants, including sortilin-related receptor (*SORL1*) \[[@B5],[@B6]\], death-associated protein kinase 1 (*DAPK1*) \[[@B7]\], ubiquilin 1 (*UBQLN1*) \[[@B8]\], adenosine triphosphate-binding cassette transporter 1, subfamily A (*ABCA1*) \[[@B9]\], and low-density lipoprotein receptor-related protein 6 (*LRP6*) \[[@B10]\]. Besides these findings, a large meta-analysis from the AlzGene database \[[@B11]\] reported 598 potential AD-susceptibility genes. For the past few years, genome-wide genotyping association studies brought considerable success by reporting new susceptible loci for AD such as Golgi membrane protein 1 (*GOLM1*) \[[@B12]-[@B15]\]. Recently two groups published the two largest LOAD GWAS \[[@B16],[@B17]\]; Harold *et al*. \[[@B16]\] reported the association of SNPs in clusterin (*CLU*) and phosphatidylinositol binding clathrin assembly protein (*PICALM*), and Lambert *et al*. \[[@B17]\] reported association of clusterin (*CLU*) with LOAD and additionally reported a novel association with complement component (3b/4b) receptor 1 (*CR1*). These new findings have provided valuable insights in the genetics, neuropathologic mechanisms and pathways associated with AD.

The cerebrospinal fluid (CSF) components β-amyloid peptide (Aβ~1-42~), total tau protein (T-tau) and phosphorylated tau (P-tau~181P~) are biomarkers for AD and can be used to aid in diagnosis and to predict progression from mild cognitive impairment (MCI) to AD \[[@B18],[@B19]\]. These biomarkers can potentially be used in future applications to predict the development of MCI in cognitively normal subjects, progression to AD in MCI patients, and to monitor AD progression \[[@B20]-[@B23]\]. These biomarkers may also be used to reveal genes that are important in AD pathogenesis. In the present study, we assessed the several putative AD genes associated with CSF biomarkers that were identified from major public GWAS dataset for Alzheimer\'s disease, the Alzheimer\'s disease Neuroimaging Initiative (ADNI). This initiative is the most comprehensive effort to identify neuroimaging measures and biomarkers associated with cognitive and functional changes in healthy elderly people and in people who have MCI and AD \[[@B24]\]. The ADNI data is useful for researchers who are searching for genes that contribute to the development of Alzheimer\'s disease, which currently affects more than 4.5 million people in the United States alone. We also investigated possible associations of CSF biomarkers (Aβ~1-42~, T-tau, and P-tau~181P~) with the number of *APOE*ε4 allele, age and *APOE*genotype in order to improve the characterization of the CSF biomarkers and genome-wide SNP genotyping data from the ADNI cohort. This is the first genome-wide association study to use these AD-related biomarkers to identify genes critical the pathogenesis of AD.

Methods
=======

Sample
------

Data used in the preparation of this article were obtained from the Alzheimer\'s Disease Neuroimaging Initiative (ADNI) database <http://www.loni.ucla.edu/ADNI>. ADNI was launched in 2003 by the National Institute on Aging (NIA), the National Institute of Biomedical Imaging and Bioengineering (NIBIB), the Food and Drug Administration (FDA), private pharmaceutical companies and non-profit organizations, as a \$60 million, 5-year public-private partnership. The primary goal of ADNI has been to test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment (MCI) and early Alzheimer\'s disease (AD). Determination of sensitive and specific markers of very early AD progression is intended to aid researchers and clinicians to develop new treatments and monitor their effectiveness, as well as lessen the time and cost of clinical trials.

The Principle Investigator of this initiative is Michael W. Weiner, M.D., VA Medical Center and University of California - San Francisco. ADNI is the result of efforts of many co-investigators from a broad range of academic institutions and private corporations, and subjects have been recruited from over 50 sites across the U.S. and Canada. The initial goal of ADNI was to recruit 800 adults, ages 55 to 90, to participate in the research \-- approximately 200 cognitively normal older individuals to be followed for 3 years, 400 people with MCI to be followed for 3 years, and 200 people with early AD to be followed for 2 years. For up-to-date information see <http://www.adni-info.org>.

The GWAS dataset (downloaded from ADNI website in June 2009) consisted of 243 normal, 235 MCI and 340 AD subjects genotyped using the Illumina Human Genome 610 Quad BeadChips. 410 of these subjects (119 Normal, 115 MCI and 176 AD; 247 males and 163 females) have CSF Aβ~1-42~, T-tau, and P-tau~181P~levels. Detailed protocols for subject recruitment and biomarker accrual are available at the ADNI website <http://www.adni-info.org/>. Demographics, CSF biomarkers, and *APOE*genotype data of the ADNI dataset are summarized in Table [1](#T1){ref-type="table"}, Table [2](#T2){ref-type="table"} and Additional file [1](#S1){ref-type="supplementary-material"}.

###### 

Demographic, clinical and biomarker data for each subject group after removing 20 outliers (n = 390: Normal, MCI and AD)

  Normal (n = 109)                Mean
  ------------------------------- ----------
  Age (year)                      71.7
  CSF Aβ~1-42~levels (pg/ml)      205.8
  CSF P-tau~181P~levels (pg/ml)   25.4
  CSF T-tau levels (pg/ml)        71.8
  Last MMSE                       29
                                  
                                  **N**
                                  
  Male                            59
  Female                          50
                                  
  **MCI (n = 109)**               **Mean**
                                  
  Age (year)                      70
  CSF Aβ~1-42~levels (pg/ml)      170.4
  CSF P-tau~181P~levels (pg/ml)   33.7
  CSF T-tau level (pg/ml)         99.5
  Last MMSE                       26.5
                                  
                                  **N**
                                  
  Male                            72
  Female                          37
                                  
  **AD (n = 172)**                **Mean**
                                  
  Age (year)                      71
  CSF Aβ~1-42~levels (pg/ml)      144.7
  CSF P-tau~181P~levels (pg/ml)   40.3
  CSF T-tau levels (pg/ml)        115.3
  Last MMSE                       21.1
                                  
                                  **N**
                                  
  Male                            105
  Female                          67

Abbreviations: CSF, cereb al spinal fluid; MMSE, Mini Mental State Examination

###### 

*APOE*genotype data for each subject group (Normal, MCI and AD)

  *APOE*genotype data (after removing outliers: n = 390)                                                                           
  ------------------------------------------------------------ ------- ----------- ----------- ----------- ----------- ----------- -----------
                                                                                                                                   
                                                                                                                                   
  ***APOE*genotype**                                                   **ε2/ε2**   **ε2/ε3**   **ε2/ε4**   **ε3/ε3**   **ε3/4**    **ε4/ε4**
                                                                                                                                   
  Normal (n = 109)                                             **n**   0           18          2           66          21          2
  MCI (n = 109)                                                **n**   0           10          2           47          40          10
  AD (n = 172)                                                 **n**   0           1           3           54          81          33
                                                                                                                                   
  ***APOE*allele**                                                     **ε2**                  **ε3**                  **ε4**      
                                                                                                                                   
  Normal (n = 109)                                             **n**   20                      105                     25          
  MCI (n = 109)                                                **n**   12                      97                      52          
  AD (n = 172)                                                 **n**   4                       136                     117         
                                                                                                                                   
                                                                                                                                   
  ***APOE*genotype data before removing outliers: n = 410)**                                                                       
                                                                                                                                   
                                                                                                                                   
                                                                                                                                   
  ***APOE*genotype**                                                   **ε2/ε2**   **ε2/ε3**   **ε2/ε4**   **ε3/ε3**   **ε3/ε4**   **ε4/ε4**
                                                                                                                                   
  Normal (n = 119)                                             **n**   0           20          2           71          24          2
  MCI (n = 115)                                                **n**   0           10          2           52          41          10
  AD (n = 176)                                                 **n**   0           2           3           54          83          34
                                                                                                                                   
  ***APOE*allele**                                                     **ε2**                  **ε3**                  **ε4**      
                                                                                                                                   
  Normal (n = 119)                                             **n**   22                      115                     28          
  MCI (n = 115)                                                **n**   12                      103                     53          
  AD (n = 176)                                                 **n**   5                       139                     120         

Abbreviations: CSF, cerebral spinal fluid

Genotyping and sample quality control
-------------------------------------

Quality control for the genotyping data was performed using PLINK <http://pngu.mgh.harvard.edu/~purcell/plink/>\[[@B25]\] as follows. 498,205 SNPs were retained after excluding SNPs with Minor Allele Frequency (MAF) \< 5%, call rate \< 98%, or significant in Hardy-Weinberg Equilibrium test (p ≤ 10^-6^). All samples had genotyping call rate \> 95% and were retained. We then examined population stratification by visual inspection using the first two dimensions from principal components analysis, using SmartPCA from EIGENSTRAT <http://genepath.med.harvard.edu/~reich/Software.htm>\[[@B26],[@B27]\]. Self-reported ethnicity and racial identities for ADNI subjects were used to highlight samples in the PCA plot and are summarized in Additional file [2](#S2){ref-type="supplementary-material"}. 390 samples were retained after SmartPCA excluded 20 samples as outliers. We computed the top five principal component coordinates using SmartPCA to correct for stratification in association analysis. SmartPCA removed all but one of the Asian samples and retained Black/African Americans (Additional file [3](#S3){ref-type="supplementary-material"}); Visual inspection suggests that the first principal component (PC0), which explains the most variance in the data, separates the Caucasians and non-Caucasians reasonably well (setting threshold PC0 \< = 0.01 can exclude all non-Caucasians). Finally, we excluded 52 non-Caucasian samples as outliers; the genomic control variance inflation factor λ was 1.00983, suggesting minimal population admixture in the final sample used for association analysis. We performed association analysis using age and APOE ε4 genotype as covariate and did not incorporate principal components. Quantile-Quantile plots for each of the three test groups with log10-transformed level of three CSF biomarkers (Additional file [4](#S4){ref-type="supplementary-material"} and Additional file [5](#S5){ref-type="supplementary-material"}) suggested that population stratification having negligible bias on the genetic associations (Additional file [6](#S6){ref-type="supplementary-material"}). Finally, for the whole analysis we performed in the following method section, the study sample of 390 individuals with three CSF biomarkers was used after removing 20 outliers. The level of three CSF biomarkers was log10-transformed.

Effect of *APOE*ε4 copy number on CSF biomarker levels
------------------------------------------------------

We performed Kruskal-Wallis test of log~10~-transformed CSF biomarkers (Aβ~1-42~, T-tau, and P-tau~181P~) stratified by the number of APOE ε4 alleles and the APOE genotypes across all 390 samples or within each of the three diagnostic groups.

Association testing of SNPs and CSF analysis
--------------------------------------------

We tested SNP association with the three CSF biomarkers (Aβ~1-42~, T-tau, and P-tau~181P~) by PLINK using samples and SNP markers passing QC. CSF biomarker levels were log~10~-transformed so they become normally distributed. The association analysis used a full linear model comprising three genetic effects: additive effects of allele dosage (ADD), dominance deviation from additivity (DOMDEV) (negative means the allele is recessive), and 2-df joint test of both additive and dominance (GENO_2DF). In addition, we used age (of being recruited by the study) and APOE ε4 genotype (number of APOE ε4 allele; 0, 1, 2) as covariates after removing outliers. To ensure the significance is not due to population stratification, we also incorporated the top five PCA principal components in the linear regression to further control for the population structure, but found the addition has very little effect on the statistical significance.

Gene ontology and E-SNP analysis
--------------------------------

We carried out gene ontology analysis of SNP association results using ALIGATOR (Association LIst Go AnnoTatOR) \[[@B28]\], to find gene-ontology terms enriched with significant SNPs. We used p-value cutoff \< 10^-3^for SNPs, 5000 replicate gene lists and 1000 permutations as parameters to run ALIGATOR. We examined the top associated SNPs and examined nearby SNPs in linkage disequilibrium (LD) that are associated with gene expression from published eQTL studies \[[@B29]-[@B33]\].

Results and Discussion
======================

Association of SNPs with CSF biomarkers
---------------------------------------

We summarize the top SNPs (p-value \< 10^-6^) with and without using covariates (APOE genotype and age) in Table [3](#T3){ref-type="table"}. Without using covariates, we found some genes near the top SNPs, including *CYP19A1*(rs2899472, p = 1.86 × 10^-7^) and *TOMM40*(rs2075650, p = 3.03 × 10^-7^) from Aβ~1-42~in normal subject. Several genetic studies have identified those genes as putative susceptible loci and genetic variants associated with Alzheimer\'s disease \[[@B34],[@B35]\]. However, close examination of nearby SNPs showed rs2899472 and rs2075650 were not supported by nearby SNPs in LD (nearby SNPs in LD are all non-significant). Because APOE genotypes are strongly associated with AD and TOMM40 is physically close to APOE, we focused on SNPs from adjusted results that consider APOE genotype and age. Here, we found 10 SNPs significantly associated with CSF biomarker level of Aβ~1-42~, 3 SNPs from T-tau, and 2 SNPs from P-tau~181P~at 10^-6^significance level in normal subjects (Figure [1](#F1){ref-type="fig"}). In addition, we found 1 SNP significantly associated with CSF biomarker level of Aβ~1-42~, 3 SNPs from T-tau, and 2 SNPs from P-tau~181P~at 10^-6^significance level in MCI subjects (Figure [2](#F2){ref-type="fig"}). No SNPs were found at 10^-6^significance level in AD subjects (Figure [3](#F3){ref-type="fig"}). For normal subjects, we found genes near the top SNPs, included *CYP19A1*(rs2899472, p = 1.90 × 10^-7^), *NCAM2*(rs1022442, p = 2.75 × 10^-7^) for Aβ~1-42~association and *UPP2*(rs2074955, p = 2.07 × 10^-7^) for P-tau~181p~association. Again, close examination of SNPs in LD with rs2899472 (CYP19A1) did not support rs2899472. The SNP rs1022442 was in close to genome-wide significance, supported by nearby SNPs (Figure [4](#F4){ref-type="fig"}), and *NCAM2*(neural cell adhesion molecule 2) gene was reported as a genetic factor related to the progression of AD in the Japanese population \[[@B36]\]. The Aβ~1-42~level grouped by the SNP rs1022442 genotype over all three cohorts (normal, MCI and AD) supports our finding (Figure [5](#F5){ref-type="fig"}). Boxplots of Aβ~1-42~levels in normal subjects stratified by rs1022442 genotype showed significant differences between AA, AB and BB. Previous study indicated an increased risk associated with rs2899472 in AD patients, which was amplified in APOE ε4 carriers in their study \[[@B35]\]. For MCI subjects, we found several genes near the top SNPs, included *FLJ21511*(rs2768975; p = 1.96 × 10^-7^, rs6850199; p = 3.18 × 10^-7^) by T-tau association and *CHN2*(rs121724, p = 1.45 × 10^-7^), *MTUS1*(rs7842088, p = 2.12 × 10^-7^) by P-tau~181p~association.

###### 

Linear regression result for SNPs with CSF biomarkers in Normal, MCI and AD subjects (Top SNPs with p-value \< 10^-6^)

  Linear regression result without using covariates                                                                                                            
  ------------------------------------------------------------------------ ------------ -------------- -------- ---------- ---------- ---------- ------------- ------------------------------------------------------------------------
  **Normal: Aβ**~**1-42**~                                                                                                                                     
                                                                                                                                                               
  **Chromosome**                                                           **SNP**      **Position**   **A1**   **TEST**   **BETA**   **STAT**   **P-value**   **Gene Symbol, Gene Name**
                                                                                                                                                               
  15                                                                       rs2899472    49303347       A        GENO_2DF   NA         40.21      1.86E-09      CYP19A1, cytochrome p450, family 19, subfamily a, polypeptide 1
  15                                                                       rs2899472    49303347       A        DOMDEV     0.1791     5.859      5.40E-08      CYP19A1, cytochrome p450, family 19, subfamily a, polypeptide 1
  1                                                                        rs11206801   56623274       A        GENO_2DF   NA         33.14      6.37E-08      
  1                                                                        rs4431886    56624855       C        GENO_2DF   NA         33.14      6.37E-08      
  15                                                                       rs2899472    49303347       A        ADD        -0.1407    -5.699     1.11E-07      CYP19A1, cytochrome p450, family 19, subfamily a, polypeptide 1
  19                                                                       rs2075650    50087459       G        GENO_2DF   NA         30.02      3.03E-07      TOMM40, translocase of outer mitochondrial membrane 40 homolog (yeast)
  12                                                                       rs10784496   64447238       G        GENO_2DF   NA         29.98      3.09E-07      
  7                                                                        rs12534221   130938530      A        GENO_2DF   NA         27.83      9.04E-07      
  6                                                                        rs1727638    72196293       A        GENO_2DF   NA         27.69      9.71E-07      
                                                                                                                                                               
  **Normal: T-tau**                                                                                                                                            
                                                                                                                                                               
  **Chromosome**                                                           **SNP**      **Position**   **A1**   **TEST**   **BETA**   **STAT**   **P-value**   **Gene Symbol, Gene Name**
                                                                                                                                                               
  12                                                                       rs1997111    117872301      T        GENO_2DF   NA         36.66      1.10E-08      
  12                                                                       rs11069178   117852210      C        GENO_2DF   NA         31.23      1.65E-07      
  2                                                                        rs17189298   119561787      A        GENO_2DF   NA         29.51      3.90E-07      
  8                                                                        rs2935776    109699079      C        GENO_2DF   NA         28.81      5.53E-07      
  8                                                                        rs2928826    109683270      T        GENO_2DF   NA         28.73      5.77E-07      
  2                                                                        rs895401     119584178      G        GENO_2DF   NA         27.86      8.90E-07      
  2                                                                        rs893769     119556554      C        ADD        -0.1024    -5.237     8.92E-07      
                                                                                                                                                               
  **Normal: P-tau**~**181p**~                                                                                                                                  
                                                                                                                                                               
  **Chromosome**                                                           **SNP**      **Position**   **A1**   **TEST**   **BETA**   **STAT**   **P-value**   **Gene Symbol, Gene Name**
                                                                                                                                                               
  18                                                                       rs1943816    69209602       C        GENO_2DF   NA         32.09      1.08E-07      
  2                                                                        rs2074955    158686040      C        GENO_2DF   NA         32.06      1.09E-07      UPP2, uridine phosphorylase 2
                                                                                                                                                               
  **MCI: T-tau**                                                                                                                                               
                                                                                                                                                               
  **Chromosome**                                                           **SNP**      **Position**   **A1**   **TEST**   **BETA**   **STAT**   **P-value**   **Gene Symbol, Gene Name**
                                                                                                                                                               
  22                                                                       rs5998432    31075916       T        GENO_2DF   NA         27.91      8.696E-07     
                                                                                                                                                               
  **MCI: P-tau**~**181p**~                                                                                                                                     
                                                                                                                                                               
  **Chromosome**                                                           **SNP**      **Position**   **A1**   **TEST**   **BETA**   **STAT**   **P-value**   **Gene Symbol, Gene Name**
                                                                                                                                                               
  2                                                                        rs7558386    227270383      G        GENO_2DF   NA         32.09      1.08E-07      
  2                                                                        rs7558386    227270383      G        DOMDEV     0.242      5.343      5.27E-07      
  3                                                                        rs7631605    37209593       T        GENO_2DF   NA         27.71      9.60E-07      
                                                                                                                                                               
  **AD: Aβ**~**1-42**~                                                                                                                                         
                                                                                                                                                               
  **Chromosome**                                                           **SNP**      **Position**   **A1**   **TEST**   **BETA**   **STAT**   **P-value**   **Gene Symbol, Gene Name**
                                                                                                                                                               
  21                                                                       rs239713     27618347       T        GENO_2DF   NA         29.03      4.96E-07      
                                                                                                                                                               
  **AD: T-tau**                                                                                                                                                
                                                                                                                                                               
  **Chromosome**                                                           **SNP**      **Position**   **A1**   **TEST**   **BETA**   **STAT**   **P-value**   **Gene Symbol, Gene Name**
                                                                                                                                                               
  20                                                                       rs4925189    59380439       G        DOMDEV     0.1969     5.178      6.35E-07      CDH4, cadherin 4, type 1, R-cadherin (retinal)
                                                                                                                                                               
  **AD: P-tau**~**181p**~                                                                                                                                      
                                                                                                                                                               
  **Chromosome**                                                           **SNP**      **Position**   **A1**   **TEST**   **BETA**   **STAT**   **P-value**   **Gene Symbol, Gene Name**
                                                                                                                                                               
  4                                                                        rs12643654   96378840       G        GENO_2DF   NA         29.04      4.95E-07      UNC5C, unc-5 homolog C (C. elegans)
                                                                                                                                                               
  **Linear regression result using APOE genotype and age as covariates**                                                                                       
                                                                                                                                                               
  **Normal: Aβ**~**1-42**~                                                                                                                                     
                                                                                                                                                               
  **Chromosome**                                                           **SNP**      **Position**   **A1**   **TEST**   **BETA**   **STAT**   **P-value**   **Gene Symbol, Gene Name**
                                                                                                                                                               
  15                                                                       rs2899472    49303347       A        GENO_2DF   NA         53.98      1.90E-12      CYP19A1, cytochrome p450, family 19, subfamily a, polypeptide 1
  15                                                                       rs2899472    49303347       A        ADD        -0.1393    -6.925     3.85E- 0      CYP19A1, cytochrome p450, family 19, subfamily a, polypeptide 1
  15                                                                       rs2899472    49303347       A        DOMDEV     0.1614     6.425      4.15E-09      CYP19A1, cytochrome p450, family 19, subfamily a, polypeptide 1
  21                                                                       rs1022442    21277717       A        GENO_2DF   NA         30.21      2.75E-07      NCAM2, neural cell adhesion molecule 2
  10                                                                       rs2493624    19102262       G        GENO_2DF   NA         28.61      6.14E-07      
  10                                                                       rs11015839   19042893       A        GENO_2DF   NA         28.51      6.45E-07      ARL5B, adp-ribosylation factor-like 5b
  10                                                                       rs11015860   19045045       G        GENO_2DF   NA         28.51      6.45E-07      
  1                                                                        rs10911736   183689227      A        GENO_2DF   NA         28.16      7.69E-07      
  10                                                                       rs11015839   19042893       A        ADD        -0.1151    -5.257     7.87E-07      
  10                                                                       rs11015860   19045045       G        ADD        -0.1151    -5.257     7.87E-07      
  10                                                                       rs11015939   19057948       A        ADD        -0.1243    -5.219     9.25E-07      
  10                                                                       rs2495832    19114467       G        ADD        -0.1243    -5.219     9.25E-07      
  6                                                                        rs12203791   67778209       T        GENO_2DF   NA         27.68      9.76E-07      
  10                                                                       rs10763625   19074957       T        ADD        -0.124     -5.206     9.78E-07      
                                                                                                                                                               
  **Normal: T-tau**                                                                                                                                            
                                                                                                                                                               
  **Chromosome**                                                           **SNP**      **Position**   **A1**   **TEST**   **BETA**   **STAT**   **P-value**   **Gene Symbol, Gene Name**
                                                                                                                                                               
  12                                                                       rs1997111    117872301      T        GENO_2DF   NA         30.74      2.11E-07      
  2                                                                        rs17189298   119561787      A        GENO_2DF   NA         27.92      8.66E-07      
  18                                                                       rs1021599    28469054       T        GENO_2DF   NA         27.88      8.81E-07      
                                                                                                                                                               
  **Normal: P-tau**~**181p**~                                                                                                                                  
                                                                                                                                                               
  **Chromosome**                                                           **SNP**      **Position**   **A1**   **TEST**   **BETA**   **STAT**   **P-value**   **Gene Symbol, Gene Name**
                                                                                                                                                               
  18                                                                       rs1943816    69209602       C        GENO_2DF   NA         31.43      1.50E-07      
  2                                                                        rs2074955    158686040      C        GENO_2DF   NA         30.78      2.07E-07      UPP2, uridine phosphorylase 2
                                                                                                                                                               
  **MCI: Aβ**~**1-42**~                                                                                                                                        
                                                                                                                                                               
  **Chromosome**                                                           **SNP**      **Position**   **A1**   **TEST**   **BETA**   **STAT**   **P-value**   **Gene Symbol, Gene Name**
                                                                                                                                                               
  10                                                                       rs2986971    30136634       G        GENO_2DF   NA         31.88      1.20E-07      
  10                                                                       rs2986971    30136634       G        ADD        0.08328    5.228      8.88E-07      
                                                                                                                                                               
  **MCI: T-tau**                                                                                                                                               
                                                                                                                                                               
  **Chromosome**                                                           **SNP**      **Position**   **A1**   **TEST**   **BETA**   **STAT**   **P-value**   **Gene Symbol, Gene Name**
                                                                                                                                                               
  4                                                                        rs2768975    48724658       G        GENO_2DF   NA         30.89      1.96E-07      FLJ21511, hypothetical protein flj21511
  4                                                                        rs6850199    48695607       A        GENO_2DF   NA         29.93      3.18E-07      FLJ21511, hypothetical protein flj21511
  18                                                                       rs1445093    48024821       C        GENO_2DF   NA         28.14      7.75E-07      
                                                                                                                                                               
  **MCI: P-tau**~**181p**~                                                                                                                                     
                                                                                                                                                               
  **Chromosome**                                                           **SNP**      **Position**   **A1**   **TEST**   **BETA**   **STAT**   **P-value**   **Gene Symbol, Gene Name**
                                                                                                                                                               
  7                                                                        rs121724     29207970       G        GENO_2DF   NA         31.49      1.45E-07      CHN2, chimerin (chimaerin) 2
  8                                                                        rs7842088    17629409       G        GENO_2DF   NA         30.73      2.12E-07      MTUS1, mitochondrial tumor suppressor 1

Abbreviations: SNP, single-nucleotide polymorphism; ADD, additive effects of allele dosage; DOMDEV, dominance deviation from additivity, rather specifying that a particular allele is dominant or recessive; GENO_2DF, a 2 df joint test of both additive and dominance; A1, tested allele (minor allele); BETA, regression coefficient; STAT, coefficient t-statistic

![**Manhattan plots of the quantitative trait (CSF biomarkers: T-tau, P-tau~181P~and Aβ~1-42~) genome wide association analysis in normal subjects**. Colors on x-axis indicate an autosomal chromosome (from chromosome 1 to chromosome 22). The y-axis indicates p-values (-log~10~(observed p-values)). Red arrows indicate rs2899472 on chromosome 15 and blue arrow indicates rs1022442 on chromosome 21.](1471-2377-10-90-1){#F1}

![**Manhattan plots of the quantitative trait (CSF biomarkers: T-tau, P-tau~181P~and Aβ~1-42~) genome wide association analysis in MCI subjects**. Colors on x-axis indicate an autosomal chromosome (from chromosome 1 to chromosome 22). The y-axis indicates p-values (-log~10~(observed p-values)).](1471-2377-10-90-2){#F2}

![**Manhattan plots of the quantitative trait (CSF biomarkers: T-tau, P-tau~181P~and Aβ~1-42~) genome wide association analysis in AD subjects**. Colors on x-axis indicate an autosomal chromosome (from chromosome 1 to chromosome 22). The y-axis indicates p-values (-log~10~(observed p-values)).](1471-2377-10-90-3){#F3}

![**Upper image shows genes in linkage disequilibrium with the SNP rs1022442 and lower plot shows the distribution of SNP rs1022442 and nearby SNPs**. In lower plot, the x-axis indicates loci on chromosome 21 and y-axis indicates p-values (-log~10~(observed GENO_2DF p-values)). Green arrow indicates rs1022442 (p = 2.75 × 10^-7^) on loci 21277717 and pink arrow indicates rs2826629 (p = 8.40 × 10^-5^) on loci 21265887.](1471-2377-10-90-4){#F4}

![**Boxplots of Aβ~1-42~levels in normal, MCI and AD subjects stratified by rs1022442 genotype**. The x-axis indicates AA, AB and BB respectively.](1471-2377-10-90-5){#F5}

Association of *APOE*with CSF biomarkers
----------------------------------------

Previous studies suggesting that CSF Aβ~1-42~and T-tau levels are correlated with the number of *APOE*ε4 alleles \[[@B37]\]. We analyzed the distribution of levels stratified by diagnosis and the number of *APOE*ε4 in the ADNI cohort after QC (Figure [6](#F6){ref-type="fig"}) and reached the same conclusion. In the AD group, Aβ~1-42~level was inversely correlated with *APOE*ε4 allele dose. The *APOE*e4 was not associated with T-tau or P-tau~181P~levels. Analysis of *APOE*genotypes showed that ε4/ε4 is associated with CSF biomarker level of Aβ~1-42~, T-tau and P-tau~181P~(Figure [7](#F7){ref-type="fig"}).

![**Boxplots of the *APOE*ε4 copy number with CSF biomarkers in normal, MCI and AD subjects**. The x-axis indicates number of *APOE*ε4 alleles and y-axis indicates CSF biomarkers. P-values are produced by the Kruskal-Wallis test.](1471-2377-10-90-6){#F6}

![**Boxplots of the *APOE*genotype with CSF biomarkers in normal, MCI and AD subjects**. The x-axis indicates five different *APOE*genotypes and y-axis indicates CSF biomarkers. P-values are produced by the Kruskal-Wallis test.](1471-2377-10-90-7){#F7}

Pathway analysis of CSF biomarkers
----------------------------------

We ran ALIGATOR to identify top gene ontology terms associated with genes containing SNPs with higher statistical significance, and summarized the results in Additional file [7](#S7){ref-type="supplementary-material"}. We found cerebral cortex development, methionine metabolic process, actinin binding, and pallium development to be among the most significant gene ontology terms associated with CSF biomarker level of Aβ~1-42~in normal subjects. Elevation in Aβ in the cerebral cortex has been implicated in the pathophysiology of AD but its mechanism of action is unknown \[[@B38]\]. It has been known that mammals have a fully developed cortex, but the structure it evolved from pallium which is present in all vertebrates as well as the most primitive ones \[[@B39]\]. The medial pallium forms the precursor of the hippocampus. Since hippocampal disruption is one of the earliest signs for AD, pallium development might be involved in the pathophysiology AD.

E-SNP analysis of CSF biomarkers
--------------------------------

We collected eSNPs (SNPs known to be associated with the expression level of some genes) in several published expression quantitative linkage (eQTL) studies, and examined regions around significant SNPs (p \< 10^-4^) (Additional file [8](#S8){ref-type="supplementary-material"}). We found significant SNPs from Dixon *et al*. \[[@B29]\], Stranger *et al*. \[[@B31]\], and Gibbs *et al*. \[[@B33]\], but we could not find any top SNPs that are associated with gene expression from other papers \[[@B30],[@B32]\]. Dixon *et al*. \[[@B29]\] used lymphoblastoid cell lines (LCLs) derived from children both with and without asthma.

NCAM2 (Neural Cell Adhesion Molecule 2)
---------------------------------------

We obtained strong evidence that NCAM2 genotypes are associated with Aβ~1-42~levels. *NCAM2*(Ensemble: ENSG00000154654, OMIM: 602040;) is a 541Kb gene at 21q21.1 with no known alternative spicing forms. Novartis SymAtlas human tissue survey shows the gene (Affymetrix probeset ID 205669_at) is ubiquitously expressed and is highly expressed in cardiac myocytes, blood cells, and appendix. Among neuronal tissues *NCAM2*has higher expression levels in prefrontal cortex, superior cervical ganglion, and hypothalamus. The transcript (Ensembl: ENST00000400546) consists of 18 exons and encodes a 93 k-Da, 835-residue plasma membrane protein (NP_004531.2). The *NCAM2*protein architecture includes 5 IgC2 (Immunoglobulin C-2 type) domains followed by two FN3 (fibronectin type 3) domains and a transmembrane domain. The gene is conserved in chimpanzee, dog, cow, mouse, rat, chicken, zebrafish, and fruit fly; the eight-domain protein architecture is also conserved in all these organisms except for cow which has only four IgC2 domains. Little is known about *NCAM2*except that the protein interacts with prion protein \[[@B40]\] and estrogen receptor 1 (ESR1) \[[@B41]\], is involved in neuron adhesion and fasciculation of neurons, and may be involved in AD \[[@B36]\], prion disease, and Down syndrome \[[@B42],[@B43]\].

TOMM40 (translocase of outer mitochondrial membrane 40 homolog (yeast)) and CYP19A1 (Cytochrome P450, family 19, subfamily A, polypeptide 1)
--------------------------------------------------------------------------------------------------------------------------------------------

It is interesting to note that we found no significant association in *APOE*(rs769451, chr19: 50102751, p = 0.6682 for association with Aβ~1-42~level in normal subjects), but a SNP with strong association in the nearby *TOMM40*(intronic SNP rs2075650, chr19:50087459, p = 3.03 × 10^-7^for association with Aβ~1-42~level in normal subjects), when age and the number of APOE e4 alleles were not included in the regression. The *TOMM40*gene is related to how easily molecules can get into and out of the surface of the mitochondria, the energy center of cells. This gene is a transporter of proteins across the mitochondrial membrane, and Sortillin-related receptor, which functions to partition amyloid precursor protein away from β-secretase and -secretase \[[@B44]\]. This is consistent with observations that levels are reduced in the brains of patients with Alzheimer\'s disease and MCI \[[@B44]-[@B46]\]. The *TOMM40*gene has been reported in numerous studies in the study of AD genetics; for example, Yu *et al*. \[[@B47]\] reported possibility that loci in the *TOMM40*gene may have a less effect on the risk for LOAD in Caucasians \[[@B47]\], and recently Roses *et al*. \[[@B48]\] found evidence supporting a poly-T polymorphism (rs10524523, chr19:50094889) in *TOMM40*affecting the AD age of onset in two independent clinical cohorts. The potential association of *TOMM40*and Aβ~1-42~may be how the gene affects the risk and onset age of AD and should be further investigated.

The *CYP19A1*gene is localized on chromosome 15q21.2 and spans 123 kb. This gene encodes a member of the cytochrome P450 superfamily of enzymes. Cytochrome P450 aromatase is an enzyme that catalyses the conversion of androgens, such as testosterone, to oestrogens, which act as sex steroid hormones but also function during growth and differentiation. There are high levels of expression in both the gonads and the brain \[[@B35]\]. Huang *et al*. \[[@B35]\] indicated an increased risk associated with SNP rs2899472 in the total number of AD patients, which was amplified in APOE ε4 carriers.

Conclusions
===========

Our analysis of the ADNI genome-wide association study identified several putative loci that are in genetic association with Aβ~1-42~, T-tau and P-tau~181P~levels in cerebrospinal fluids. In particular an intronic SNP rs1022442 of gene *NCAM2*is close to genome-wide significance in association with Aβ~1-42~in normal subjects. Although the gene is poorly characterized in the literature, prior studies have implicated roles of *NCAM2*in prion disease, Down syndrome, and AD. Our findings suggest *NCAM2*could be part of the pathway on the pathogenesis of senile plaques in human brains with AD.

With only 119 normal subjects and 410 overall, the GWAS dataset is clearly underpowered. The most significant associations were identified using normal subjects since the variances of the CSF biomarker levels are much smaller in MCI and AD subjects due to dementia. Nonetheless, increasing the number of CSF biomarker measurements is challenging especially for normal subjects. An alternative that will substantially increase the sample size is to examine protein levels in blood instead of CSF, given levels of these proteins in blood are informative about AD pathology or prognosis \[[@B49]\].

Our analysis clearly demonstrates that quantitative trait linkage of biomarkers via genome-wide screening can reveal additional insights into the mechanism that connects known genetic factors to the disease \[[@B50]\]. Moving along this path requires further efforts by the research community towards larger sample size and accrual of additional biomarkers in AD and other neurodegenerative disorders.
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